Description

NIFTAS SR 100 MG

Indications

NIFTAS SR 100 MG is primarily indicated for the management of hypertension and the treatment of certain types of angina pectoris. It is often prescribed for patients who require long-term management of their blood pressure levels and for those who experience chest pain due to inadequate blood flow to the heart. The sustained-release formulation allows for once-daily dosing, enhancing patient compliance and convenience.

Mechanism of Action

The active ingredient in NIFTAS SR 100 MG is nifedipine, a calcium channel blocker that selectively inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle cells. By blocking these channels, nifedipine causes relaxation of the smooth muscles in the blood vessels, leading to vasodilation. This results in a decrease in peripheral vascular resistance and a subsequent reduction in blood pressure. Additionally, the relaxation of coronary arteries improves blood flow to the heart, alleviating angina symptoms.

Pharmacological Properties

Nifedipine exhibits a rapid onset of action, typically within 20 minutes, with peak plasma concentrations occurring around 30 to 60 minutes post-administration. The sustained-release formulation of NIFTAS SR ensures a prolonged therapeutic effect, allowing for stable plasma levels over a 24-hour period. The bioavailability of nifedipine can be affected by food intake; thus, it is recommended to take the medication consistently with or without food to maintain uniform absorption. The drug is extensively metabolized in the liver, and its metabolites are primarily excreted through the urine.

Contraindications

NIFTAS SR 100 MG is contraindicated in patients with known hypersensitivity to nifedipine or any of the excipients in the formulation. It should not be used in patients with severe hypotension, cardiogenic shock, or unstable angina. Additionally, the drug is contraindicated during pregnancy and lactation unless the potential benefits outweigh the risks, and it is not recommended for pediatric patients under the age of 18.

Side Effects

Common side effects associated with NIFTAS SR 100 MG may include headache, dizziness, flushing, and peripheral edema. Some patients may experience gastrointestinal disturbances such as nausea or constipation. Serious side effects, although rare, can include hypotension, tachycardia, and allergic reactions. Patients should be advised to report any unusual symptoms or severe adverse reactions to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of NIFTAS SR 100 MG is one tablet taken orally once daily. Depending on the patient’s response and clinical condition, the dosage may be adjusted by the healthcare provider. It is crucial for patients to adhere to the prescribed regimen and not to exceed the recommended dose. The tablet should be swallowed whole and not crushed or chewed to maintain the integrity of the sustained-release formulation.

Interactions

NIFTAS SR 100 MG may interact with various medications, which can alter its effectiveness or increase the risk of adverse effects. Co-administration with other antihypertensive agents may lead to additive effects, resulting in severe hypotension. Caution should be exercised when used alongside drugs that inhibit or induce cytochrome P450 enzymes, as these can affect the metabolism of nifedipine. Patients should inform their healthcare provider of all medications, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Prior to initiating treatment with NIFTAS SR 100 MG, a thorough medical history and physical examination should be conducted. Special caution is warranted in patients with liver or kidney impairment, as dosage adjustments may be necessary. Patients with a history of heart failure or significant aortic stenosis should also be monitored closely during therapy. It is essential to regularly monitor blood pressure and heart rate to ensure the medication is achieving the desired therapeutic effect without causing adverse reactions.

Clinical Studies

Clinical studies have demonstrated the efficacy of NIFTAS SR 100 MG in reducing blood pressure and alleviating symptoms of angina. In a randomized controlled trial, patients treated with nifedipine showed significant reductions in systolic and diastolic blood pressure compared to placebo. Furthermore, studies have indicated that the sustained-release formulation provides a more stable pharmacokinetic profile, resulting in improved patient adherence and fewer side effects compared to immediate-release formulations. Long-term studies have also suggested that nifedipine may have beneficial effects on cardiovascular outcomes, although further research is needed to establish these findings definitively.

Conclusion

NIFTAS SR 100 MG is an effective and well-tolerated option for the management of hypertension and angina pectoris. Its unique sustained-release formulation allows for once-daily dosing, promoting patient adherence and convenience. However, as with any medication, it is essential for patients to be aware of potential side effects, drug interactions, and the importance of adhering to prescribed dosages. Regular follow-up with healthcare providers is crucial to monitor the effectiveness of the treatment and make any necessary adjustments.